Abbott, Novo Nordisk ink deal for digital diabetes tools

Abbott, Novo Nordisk ink deal for digital diabetes tools

Source: 
Drug Delivery Business News
snippet: 

AAbbott (NYSE:ABT) said today that it inked a non-exclusive deal to integrate insulin dose data from Novo Nordisk‘s (NYSE:NVO) pre-filled and connected pens with its FreeStyle Libre mobile app and cloud-based system.